Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

Date publication

août 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LANG Hervé , Dr LINDNER Véronique , Dr MASSFELDER Thierry

Tous les auteurs :
Lang H, Béraud C, Cabel L, Fontugne J, Lassalle M, Krucker C, Dufour F, Groeneveld CS, Dixon V, Meng X, Kamoun A, Chapeaublanc E, De Reynies A, Gamé X, Rischmann P, Bieche I, Masliah-Planchon J, Beaurepere R, Allory Y, Lindner V, Misseri Y, Radvanyi F, Lluel P, Bernard-Pierrot I, Massfelder T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36033544

Résumé

Muscle-invasive bladder cancer (MIBC) and upper urinary tract urothelial carcinoma (UTUC) are molecularly heterogeneous. Despite chemotherapies, immunotherapies, or anti-fibroblast growth factor receptor (FGFR) treatments, these tumors are still of a poor outcome. Our objective was to develop a bank of patient-derived xenografts (PDXs) recapitulating the molecular heterogeneity of MIBC and UTUC, to facilitate the preclinical identification of therapies.

Mots clés

basal tumors, luminal tumors, molecular subtypes, squamous cell carcinoma, tumor heterogeneity, tyrosine kinase receptor, upper-urinary tract carcinoma, urothelial carcinoma

Référence

Front Oncol. 2022 08 11;12:930731